In order to assess potential therapeutic interventions, our pharmacological study in the electrical SE epilepsy model showed that antiinflammatory drugs targeting the IL1-R1/TLR4 axis significantly (P < 0.05) improved the natural history of the disease and prevented elevation of the pathological disulfide isoform in peripheral blood from disease onset. This evidence concerns the gene TLR4 and epilepsy.